HTDK, a leading high-value medical device commercial solution platform in the Chinese market, and CGBio, a subsidiary of Korea-listed Dawoo known for its expertise in regenerative medicine, have announced the signing of a strategic collaboration agreement aimed at advancing the commercialization and licensing of “FACETEM” hydroxyapatite fillers in Mainland China and Macau. This agreement marks a significant milestone in the development of the medical aesthetics industry in China and showcases a commitment to providing high-quality aesthetic solutions to Chinese consumers.

Under this collaboration, HTDK will take responsibility for the marketing registration of “FACETEM” in mainland China, and upon obtaining marketing authorization, it will exclusively hold the commercialization rights for a period of ten years. CGBio, in turn, will exclusively supply “FACETEM” to HTDK once the marketing license has been granted. This strategic partnership signifies a pivotal move towards introducing a unique, FDA-approved injectable hydroxyapatite microsphere facial filler to the Chinese market.

Hydroxyapatite (CaHA), a biocompatible, non-toxic, and non-irritant material, is well-established in various medical fields, including dentistry and orthopedics, for filling bone defects. In medical aesthetics, CaHA can be processed into a nanoscale form, combined with water or hyaluronic acid, and injected under the skin’s surface to act as a facial filler. Unlike hyaluronic acid, CaHA offers longer-lasting results, can be metabolized and absorbed by the body, and has been approved by the FDA for improving facial wrinkles and folds in adults.

“Facetem,” the flagship product of this collaboration, represents a subcutaneous injection used to enhance facial appearance by reducing wrinkles. Once administered, it is absorbed and metabolized by the body, promoting collagen and elastin formation to create a new scaffolding. This unique property significantly reduces the risk of calcium hydroxyapatite dislocation, providing patients with a safe and effective aesthetic solution.

The global injectable medical aesthetics market has seen remarkable growth in hydroxyapatite fillers, making it one of the fastest-growing segments in regenerative medical aesthetics. The demand for hydroxyapatite-based procedures has surged, reflecting an evolving landscape of consumer preferences and an ever-expanding market. “FACETEM,” as one of the world’s top three hydroxyapatite fillers, is already established in 18 countries and is considered a leader in the global hydroxyapatite filler market.

Mr. Hyun Seung Yu, CEO of CGBio, expressed his confidence in the Chinese market, stating, “We believe that we will have strong competitiveness in the Chinese market. We will work closely with HTDK to obtain a license for ‘FACETEM’ in China and become a leading company in the international medical aesthetic field.”

Teresa, CEO of HTDK, also emphasized the significance of this collaboration, stating, “This cooperation marks the further development of HTDK in China’s medical aesthetic market. We look forward to working closely with CGBio to promote the successful entry of ‘FACETEM’ into the Chinese market, providing Chinese consumers with more healthy, safe, and high-quality aesthetic solutions.”

This strategic partnership between HTDK and CGBio is expected to revolutionize the medical aesthetics landscape in China and offer consumers access to cutting-edge aesthetic solutions. With “FACETEM,” the future of facial aesthetics in China looks promising, bringing a blend of innovation and safety to the forefront.